* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Botanix Pharmaceutical Investor Factsheet
Survey
Document related concepts
Neuropharmacology wikipedia , lookup
Pharmacognosy wikipedia , lookup
Epinephrine autoinjector wikipedia , lookup
Drug interaction wikipedia , lookup
Pharmaceutical marketing wikipedia , lookup
Compounding wikipedia , lookup
Drug design wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Environmental persistent pharmaceutical pollutant wikipedia , lookup
Nicholas A. Peppas wikipedia , lookup
Environmental impact of pharmaceuticals and personal care products wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Transcript
Botanix is a medical dermatology company using a novel drug active and proven drug delivery technology to develop prescription treatments for serious skin diseases, including acne, psoriasis and atopic dermatitis. It has licensed a novel drug delivery technology known as Permetrex™ which is designed to deliver pharmaceuticals into the skin more effectively than other approaches. Botanix is preparing for the first human trials delivering synthetic cannabidiol to the skin. Cannabidiol is currently being studied by many pharmaceutical companies for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications, but Botanix plans to be the first company to develop synthetic cannabidiol for skin diseases. Cannabidiol has been shown in pre-clinical studies to have a unique mechanism of action in skin disease, along with a benign side effect profile. Botanix’s target drug is very poorly absorbed if delivered orally (only about 6% gets into the blood stream), so Botanix intends on utilising a novel skin drug delivery technology called Permetrex™, which is designed to deliver pharmaceuticals into the skin more effectively than other approaches. The technology is particularly useful as: Permetrex™ does not utilise chemicals which have a tendency to dry the skin and are therefore not desirable for diseases such as acne, psoriasis and atopic dermatitis; Permetrex™ facilitates the rapid delivery of active pharmaceutical ingredients across protective layer of the skin and into the lower layers where the drug targets are situated; Permetrex™ can accommodate other formulation ingredients, which can selectively leave parts of the formulation on the skin in a protective coating for extended absorption and/or protection of the skin. Significant unmet patient needs: There has been little innovation in the field of acne treatment and there remains unmet patient and treatment need, including: the need for a topical product that inhibits production of oil or lipids by the sebaceous glands; novel actives, including a synthetic form of cannabidiol which has an established safety and efficacy profile in other diseases Novel treatments for acne with a growing evidence base: Cannabidiol has a unique mechanism of action that addresses the 4 key pathologies of acne – excessive oil production, infection, inflammation and over-proliferation of skin cells Strong management team: Botanix is rapidly advancing under a proven board and management team that have more than 10 FDA approvals between them, and a successful track record on ASX Path to market: Topical product applications are more efficient and cost effective than oral or injectable delivery antibiotic-independent mechanisms for reducing acne colonisation and infection an agent with the efficacy of the leading oral product (isotretinoin or 'Accutane'), but which is potentially free of its serious side effects. BTX1503 has the potential to meet these significant unmet patient needs Proprietary drug delivery system: Botanix has the exclusive global rights to use Permetrex™ for a class of Botanix Pharmaceuticals’ lead product under development (BTX1503) is a topically applied gel for the treatment of serious acne which utilises the novel synthetic cannabidiol active, delivered using the Permetrex™ drug delivery technology. Pre-clinical work has shown that a topical formulation if delivered effectively to the target organs in the skin, may provide a new option for patients where existing anti-bacterial and inflammation targeting medicines have failed. There is a significant unmet patient need for effective therapies in the global acne market, given the relatively few new products being developed and the recent withdrawal of products from the market, due to their significant side effect problems. Ticker Code BOT Share price $0.02 Shares on Issue 408.8m Market Capitalisation (undiluted, at issue price) $8.1m Debt $0.0m Cash raised $3.5m Graham Griffiths Matthew Callahan Chairman Executive Director Experienced ASX director and CEO with 39 years experience in technology commercialisation and sales. Former Managing Director of ipernica Ltd, now Nearmap (ASX:NEA) and director of Pointerra Ltd (ASX:3DP). Founding CEO of iCeutica Inc and Churchill Pharmaceuticals with more than 20 years life sciences, IP and investment management experience. Also a director of Glycan Bioscience LLC and Orthocell (ASX:OCC). Dr H. William Bosch Robert Towner Executive Director/Chief Scientific Adviser Non-Executive Director More than 20 years of experience in the Mr Towner was a founding Executive Director pharmaceutical industry developing products of ASX listed bioMD Limited and has over 20 for FDA approvals using drug delivery years' corporate advisory and executive technologies at Elan Corporation and iCeutica experience. Inc. Former co-founder of NanoSystems LLC and coinventor of Nanocrystal and SoluMatrix™ technology platforms. Botanix Pharmaceuticals is seeking to list on the Australian Securities Exchange. In April 2016, Bone Medical (ASX: BNE) entered into an agreement to acquire 100 percent of Botanix to facilitate Botanix’s listing. As part of the public offering, Botanix is seeking to raise $3 million (with oversubscriptions up to $500,000) under the offer at a 2 cent capital raising. Event ` Date Announcement of Acquisition 21 March 2016 Despatch Notice of Meeting 13 May 2016 Lodgement of Prospectus and Offer Open 13 May 2016 Shareholder Meeting to Approve Acquisition 14 June 2016 Suspension from Trading 14 June 2016 Offer Close 27 June 2016 Expected date for Shares to be reinstated to trading on ASX 15 July 2016 For more information on Botanix Pharmaceuticals, please visit www.botanixpharma.com Matthew Callahan +1 215 767 4184 [email protected] James Mcglew 08 9224 6866 [email protected] Rebecca Wilson 03 8866 1216 [email protected] Arthur Chan 02 9237 2805 [email protected]